a b s t r a c t G protein-coupled receptors control a wide range of physiological processes and are the target for many clinically used drugs. Understanding the way in which receptors bind agonists and antagonists, their organisation in the membrane and their regulation after agonist binding are important properties which are key to developing new drugs. One way to achieve this knowledge is through the use of fluorescent ligands, which have been used to study the expression and function of receptors in endogenously expressing systems. Fluorescent ligands with appropriate imaging properties can be used in conjunction with confocal microscopy to investigate the regulation of receptors after activation. Alternatively, through the use of single molecule microscopy, they can probe the spatial organisation of receptors within the membrane. This review focuses on the techniques in which fluorescent ligands have been used and the novel aspects of G protein-coupled receptor pharmacology which have been uncovered. This article is part of the Special Issue entitled 'Fluorescent Tools in Neuropharmacology'.
Introduction
The membrane bound G protein-coupled receptors (GPCRs) are the largest family of proteins in the human genome and mediate a wide range of biological processes (Bockaert and Pin, 1999) . Due to their integral membrane location, they allow the transmission of a signal from the outside of a cell to the intracellular environment through the binding of an agonist, such as a neurotransmitter or hormone. Agonist binding causes conformational changes in the receptor which leads to the direct activation of intracellular signalling proteins (e.g. GTP binding proteins, b-arrestins) which in turn can trigger numerous downstream signalling cascades. The role that GPCRs play in regulating a multitude of cellular responses and their tractability as membrane proteins has led to this receptor family being one of the most successful drug targets, with the most recent estimates ascribing 26% of currently approved pharmaceuticals as acting at GPCRs (Garland, 2013) . Despite this success, these drugs only target around 30% of non-olfactory GPCRs which leaves over 70% as potential targets for novel pharmaceuticals, many of which have been implicated in disease pathology (Garland, 2013) . There is a growing sense that screening of millions of compounds at a given GPCR may not be the most effective way of identifying new candidate molecules, but rather that understanding the unique pharmacology of an unmodified receptor in its native environment has a greater potential to lead to more efficient drug discovery programmes.
One way to study unmodified GPCRs in their native cellular environment is through the use of fluorescent techniques, in particular fluorescent agonists or antagonists that bind selectivity to the receptor of interest. Fluorescent ligands have been developed for a wide range of peptide and non-peptide GPCRs and generally consist of an agonist or antagonist molecule conjugated via a linker to a fluorescent moiety. It has generally proved to be more challenging to generate non-peptide fluorescent ligands due to their relatively small molecular weight, which is substantially increased by the attachment of a linker and fluorophore.
This review will focus on describing the novel aspects of pharmacology that can be probed by using fluorescent ligands and relate this to the function that they are able to reveal. The main techniques discussed in this review are depicted in Fig. 1 . The examples below are not intended to be an exhaustive list of fluorescent ligands that have been used to study receptor pharmacology, which have been described comprehensively in a recent review (Sridharan et al., 2014) , but it will detail their advantages and use examples from the literature in which they shine new light on the function of particular GPCRs. A schematic representing the range of techniques in which fluorescent ligands can be used to investigate GPCR molecular pharmacology. The centre panel shows an example fluorescent ligand (CA200645) highlighting the pharmacophore, fluorophore and linker regions. Laser scanning confocal microscopy (A) uses an adjustable pinhole to allow high resolution imaging. A laser beam passes through the pinhole aperture, is reflected off a dichromatic mirror and then focused via the objective onto a single focal plane of the fluorescent specimen. Both in focus and out of focus fluorescence emitted from the specimen travels back through the objective, to a detector pinhole. In focus light is focused through the detector pinhole, where it is detected by the photomultiplier, whereas extraneous out of focus light is largely not. Automated confocal platereaders (B) allow high content imaging to be performed on a higher throughput scale (6e1536 well plates) than that capable using manual confocal microscopy. Fluorescence correlation spectroscopy (FCS) can be used to study the mobility of fluorescently labelled moieties through a confocal volume of defined dimensions of typically 0.25e0.5 fl (C). Upon diffusing through the confocal volume, fluorescent molecules are excited (red star) and produce time dependent fluctuations in fluorescence. These can be analysed in a time dependent manner using autocorrelation analysis to provide information on the mobility and concentration of fluorescent particles present within the confocal volume. Total internal reflection fluorescence microscopy (TIRF-M) exploits the difference in refractive indices of two different mediums (in this case glass and the specimen) to minimise background fluorescence and provide single molecule sensitivity (D). When light hits this interface at a specific angle (termed the critical angle) it results in the incident light being totally internally reflected generating an evanescent wave. The evanescent wave penetrates only typically 100 nm into the sample and decays exponentially with distance from the interface (shown by blue shading), allowing the selective excitation of fluorophores in thin cellular regions close to the interface (eg. basal membranes). Fluorescence activated cell sorting (FACS) allows the sorting of heterogenous cell mixtures based on their fluorescence properties (E). A suspension of cells is forced through a column, at a single cell per droplet flow, whereby they pass through a laser beam. Scattered and fluorescent light is filtered and detected (detector 1 and 2), with cells separated into distinct populations allowing the relative amount of bound ligand to be determined. Time resolved fluorescence resonance energy transfer (TR-FRET) can be used to investigate the molecular interactions of, in this example, fluorescently labelled GPCRs and fluorescent ligands in living cells (F). Close proximity of fluorescent ligand and receptor, facilitates the transfer of energy between donor (blue circle) and acceptor (red star) fluorophores (FRET; black lightning arrow). Donor or acceptor fluorophores can be attached to either the receptor or ligand of interest. In TR-FRET, lanthanides are used as donor fluorophores as their long emission lifetime allows measurements to be made following a time delay which increases sensitivity, minimises the impact of background fluorescence and allows the technique to be used in situ.
What are fluorescent ligands?
Fluorescent ligands for GPCRs are generated by taking a pharmacophore, which is usually a known agonist or antagonist for the receptor of interest, and conjugating it to a small organic fluorophore . Although many different fluorophores have been effectively used to generate useful fluorescent ligands the main classes of fluorophores used have been the BODIPY series (Allen et al., 2000; Baker et al., 2011; Daly et al., 2010; Tomasch et al., 2012b; Vernall et al., 2012) , the Alexa series (Arttamangkul et al., 2000; Brand et al., 2008; Corbani et al., 2011; Morishima et al., 2010) and rhodamine derivatives (Castro et al., 2005; Daly et al., 2010; Guo et al., 2012) . Fluorescent ligands containing these fluorophores have been effectively used in many of the techniques detailed below with the exception of certain time-resolved fluorescence resonance energy transfer (TR-FRET) studies in which europium linked fluorescent ligands were developed to provide a signal with a long fluorescence lifetime (Albizu et al., 2010) . For many peptide based fluorescent ligands, amine-or thiol-reactive fluorophores can be directly coupled to the peptide ligand via reactive lysine or cysteine amino acid side chains (Arttamangkul et al., 2000; Harikumar et al., 2006) . For small molecule ligands, however, a linker is generally required to separate the pharmacophore from the fluorophore to allow access of the pharmacophore to the transmembrane orthosteric binding site. The composition and length of this linker can have major effects on both the pharmacological, physicochemical and photophysical properties of the resulting fluorescent ligands (Baker et al., 2010 (Baker et al., , 2011 Vernall et al., 2013) . In addition, these properties are also heavily influenced by the choice of fluorophore which can change fluorescent ligand affinity, photophysics and lipid solubility (Baker et al., 2010; Vernall et al., 2013) . For these reasons, each new fluorescent ligand, both peptide and small molecule, must be considered as a completely new pharmacological entity compared to the parent ligand and be fully characterised before use in further studies. Comprehensive reviews on fluorescent ligands for GPCRs have recently been published which contain the structures of many of the ligands mentioned below as it beyond the scope of the present review to discuss the chemistry behind these molecules in detail (Kozma et al., 2013; Kuder and Kiec Kononowicz, 2014; Vernall et al., 2014) .
Fluorescent ligands as alternatives to radioligands in competition binding assays
The initial step in the identification of a new drug-like molecule for a GPCR is to determine its affinity at the receptor of interest. This is often achieved by monitoring binding of a radiolabelled receptor ligand, but due to the disposal and safety concerns surrounding the use of large quantities of radiochemicals an alternative to these assays has been sought. Fluorescent ligands are a viable solution to this issue as they can be used in many of the same ways as radioligands. There have been various attempts to develop assays that use fluorescent ligands to determine the affinity of unlabelled ligands and these have been reviewed previously (Cottet et al., 2011) . These have included the use of fluorescence resonance energy transfer (FRET) techniques (Zwier et al., 2010) , fluorescence polarisation (Allen et al., 2000) and flow cytometry (Young et al., 2005) . More recently, a method has been described for the adenosine-A 1 and -A 3 receptors in which the binding of the fluorescent ligand, CA200645, to the receptor was measured directly using automated confocal imaging . The CA200645 ligand consists of the non-selective adenosine receptor antagonist xanthine amine cogener (XAC) linked to the red BODIPY630/650 fluorophore via a b-alanine linker. To estimate the levels of fluorescent ligand bound to CHO cells expressing the adenosine-A 1 or -A 3 receptor, a confocal imaging plate reader was used to automatically capture images from a multi-well plate and the integrated fluorescence intensity of the resulting images was used as a measure of ligand binding (Fig. 2) . This assay was also capable of detecting the binding of low molecular weight fragments to both the A 3 and A 1 receptors . Fragment-based drug discovery (FBDD) is becoming a widely used tool in drug discovery as it often results in lead compounds with a lower molecular weight and complexity than traditional methods (Hopkins et al., 2004) . GPCR FBDD is often carried out with biophysical techniques using purified receptors, therefore the ability to carry out FBDD in live cells, and potentially in endogenously expressing systems, may also help develop new molecular entities for targeting therapeutically important GPCRs. In addition to screening for fragment like ligands, fluorescent ligands have been used for identifying new molecules for a range of GPCRs. For instance, Iturrioz et al., used a fluorescent ligand in a FRET based system which enable them to identify the first small molecule agonist for the apelin receptor which may lead to new molecules being developed for the treatment of heart failure (Iturrioz et al., 2010) . Also, in a flow cytometry based system, new non-peptide small molecule ligands for the formylpeptide receptor were identified from a library of 880 compounds using a fluorescein labelled formylmethionine-leucine-phenylalanine-lysine (Young et al., 2005) . This demonstrates that together with fragment screening, fluorescent ligands may be able to replace radioligands in many of the early drug discovery processes.
The direct measurement of fluorescent ligand binding has also been used to characterise new antagonists at the adenosine-A 1 and -A 3 receptors. Using a fluorescent antagonist that emits at green wavelengths, the assay can be adapted to determine the affinity of fluorescent antagonists emitting at red wavelengths and vice versa (Vernall et al., 2013) . Although the throughput of this system is not as high as for FRET or fluorescence polarisation assays (Allen et al., 2000; Veiksina et al., 2014; Zwier et al., 2010) , one advantage of this imaging-based technique is the ability to simultaneously determine the affinity and efficacy of an unknown ligand and potentially to correlate this to what is happening at the single cell level.
Fluorescent ligands can also be used over a much wider concentration range than radiolabelled ligands and provide scope for determining binding to multiple conformational states. For example, the ligand CGP 12177 is a b-adrenoceptor ligand that has been shown to antagonise agonist-mediated responses at the high affinity catecholamine binding site of the b 1 -adrenoceptor but also to have agonist activity at higher concentrations through binding to a secondary low affinity receptor conformation (Baker et al., 2003; Konkar et al., 2000) . Use of a fluorescent derivative of CGP 12177 (BODIPY-TMR-CGP) over a wide concentration range allowed the detection and characterisation of both sites at the b 1 -adrenoceptor (Gherbi et al., 2014) .
Use of fluorescent ligands to study receptor expression patterns

Required properties of a fluorescent ligand
One obvious, but challenging, use of fluorescent GPCR ligands is in conjunction with microscopy to study the cellular and tissue localisation of a receptor. Many of the studies detailed below use confocal microscopy to obtain images. Confocal microscopy uses a laser to illuminate the sample coupled with a pinhole to eliminate out of focus light which allows a single plane of the sample to be visualised. To perform useful microscopy studies, a fluorescent ligand for a GPCR needs to show discrete plasma membrane binding which can be blocked by an unlabelled ligand, and low levels of non-specific binding (including intracellular fluorescence). There are many examples in the literature of fluorescent ligands with good imaging properties, including those for the vasopressin and oxytocin receptors (Corbani et al., 2011) , kappa opioid receptor (Houghten et al., 2004) , b 2 adrenergic receptor (Baker et al., 2011) , adenosine-A 3 receptor and the leukotriene B 4 Fig. 3 . Comparison of fluorescent ligands with and without high levels of non-specific binding. CHO cells expressing the adenosine-A 3 receptor were treated with 30 nM XAC-X-BY630 (pK D ¼ 7.5) (top panels) or 0.5 nM XAC-Ala-Ser-X-BY630 (pK D ¼ 9.3) (bottom panels) (Vernall et al., 2013) for 30 min in the absence (left hand panels) or presence (right hand panels) of 100 nM MRS1220 to inhibit specific receptor binding. Approximate K D (values taken from Vernall et al., 2013) concentrations of each of the ligands were chosen to give 50% occupancy in both cases. Images were obtained using Zeiss LSM510 Meta NLO confocal microscope. Both ligands show membrane localisation of the fluorescence in the absence of unlabelled antagonist. XAC-X-BY630 shows high levels of intracellular fluorescence in the presence of unlabelled antagonist whereas there is very little non-specific fluorescence in MRS1220-treated cells incubated with XAC-Ala-Ser-X-BY630. All images shown were obtained on the same day with identical microscope settings for power offset and gain.
receptor (Sabirsh et al., 2005) . Recent work in our laboratory has focused on the development of fluorescent ligands for the adenosine receptors with improved imaging properties. We found that inclusion of a peptidic linker in an XAC-BODIPY630/650 conjugate improved its affinity and significantly reduced the levels of intracellular non-specific binding (Vernall et al., 2013) compared to a direct XAC-BODIPY630/650 (XAC-X-BY630) conjugate (Fig. 3 ) . Their improved affinity also allowed them to be used at lower concentrations with the same degree of receptor occupancy which is beneficial in reducing levels of non-specific binding. Developing a new fluorescent ligand for a GPCR often focuses on retaining the high affinity of the parent pharmacophore. However, high affinity per se does not necessarily mean that the resulting fluorescent ligand will be optimal for imaging studies. For example, a fluorescent ligand for the histamine-H 1 receptor (mepyramine-X-BY630) displayed similar affinity for the receptor as the parent ligand mepyramine but showed very high levels of non-specific binding which prevented its use in confocal imaging studies (Rose et al., 2012) .
Use of fluorescent ligands in endogenous systems
Once a fluorescent ligand has been shown to have appropriate imaging properties it can be used to probe the expression pattern of the receptor in natively expressing systems. Morishima and coworkers demonstrated the discrete localisation of the fluorescence to the muscle layer of human prostate using a fluorescent a 1B adrenergic receptor antagonist (Morishima et al., 2010) . Similarly, using a fluorescent antagonist for the prostanoid EP 3 R, it was shown that the EP 3 R was expressed in murine kidney and in human brain tissue (Tomasch et al., 2012a) . In T lymphocytes, a CXCL12 based fluorescent ligand has been used in conjunction with both microscopy and flow cytometry to identify CXCR4 positive Tlymphoid SupT1 cells (Hatse et al., 2004) and expression of the CB2 receptor on CD4þ T cells was demonstrated using a fluorescent ligand for the cannabinoid CB2 receptor (Petrov et al., 2011) . For the neuropeptide Y 1 receptor (Y 1 R), the development of a small molecule fluorescent antagonist allow the confirmation of the expression of the receptor in a human breast cancer cell line (MCF-7) and interestingly using flow cytometry they showed that they could measure the affinity of unlabelled antagonists in a erytholeukemia cell line that endogenously expresses the Y 1 R (Schneider et al., 2007) . Daly et al. (2010) simultaneously used three spectrally discrete fluorescent ligands to investigate the distribution of aadrenoceptors, b-adrenoceptors and the cannabinoid-like receptor, GPR55, in mouse arteries at the level of single cells (Daly et al., 2010) . They showed that in mouse vascular smooth muscle there was a heterogeneous expression of all three receptor subtypes, with some cells expressing all three receptors and others expressed only the a 1 -and b-adrenoceptors. In contrast, they also demonstrated the colocalisation of a 1 adrenoceptors and GPR55 within the mesenteric arteries (Daly et al., 2010) . There are three a 1 -adrenoceptor subtypes (a 1A, a 1B and a 1D ) and the localisation of these subtypes have been studied using the a non-selective fluorescent a 1 receptor antagonist BODIPY-FL-prazosin (QAPB) in the arteries of mice. Using QAPB in a 1A/B, or a 1B/D knock-out mice differences in the localisation of a 1A, and a 1D subtypes in mesenteric and carotid arteries were found (Methven et al., 2009a (Methven et al., , 2009b . Additionally, it was shown that the a 1D receptor is found both at the cell surface and intracellularly, and this has been proposed to play in a role in the observed pharmacology of this receptor (Methven et al., 2009b) . A fluorescent derivative of the parathyroid hormone (PTH) has been used to visualise the expression of the PTH receptor in the proximal tubule of mice kidneys. The authors extended the use of this fluorescent ligand to show the colocalisation of the receptor with scaffold proteins such as ezrin and interestingly demonstrated that the expression pattern of the receptor changes upon hyperparathyroidism (Guo et al., 2012 ). These studies demonstrate the power of fluorescent ligands to improve our understanding of the expression pattern of receptor subtypes and their potential for interactions. Fluorescent ligands can also shed light on unknown functions of receptors. This has been recently demonstrated for the adenosine-A 3 receptor (Corriden et al., 2013) again through the use the fluorescent adenosine receptor antagonist, CA200645. Confocal microscopy demonstrated that the A 3 receptor was highly enriched in microdomains of human neutrophils which were at the base of membrane projections which the authors showed were involved in the long-range capture of pathogens. Furthermore, the presence of an adenosine receptor agonist increased the number of these projections demonstrating a previously unknown role of the A 3 receptor in neutrophil function (Corriden et al., 2013) .
Studying receptor internalisation using fluorescent ligands
Many GPCRs are known to internalise in response to agonist exposure, and fluorescent agonists for GPCRs can also internalise receptors or result in clustering of the fluorescent ligand occupied receptors within the cell and on the cell membrane, as demonstrated for the m and d opioid receptor (Arttamangkul et al., 2000) adenosine-A 2A receptor (Brand et al., 2008) , AT 1 angiotensin receptor (Hunyady et al., 2002) and neuropeptide Y 1 receptor (Ziemek et al., 2006) heterologously expressed in non-natively expressing systems. More excitingly, this opens up the possibility of visualising reorganisation and regulation of endogenously expressed GPCRs. Arttamangkul and co-workers, for instance, extended the use of their fluorescent agonist (Arttamangkul et al., 2000) to study the internalisation and desensitisation of endogenously expressed m opioid receptor in a primary cell line derived from mouse locus coeruleus neurones (Arttamangkul et al., 2006) . They demonstrated that in these cells the fluorescent agonist induced receptor clustering and internalisation, and that by blocking this internalisation with concanavalin A the decrease in membrane potential induced by receptor activation still underwent desensitisation thus showing that receptor internalisation of the m opioid receptor is not a pre-requisite for desensitisation (Arttamangkul et al., 2006) . There are still many unanswered questions regarding receptor internalisation and the termination of the agonist signal with recent reports showing that an internalised receptor can continue to signal (Calebiro et al., 2010; Irannejad et al., 2013 Irannejad et al., , 2014 . Fluorescent agonists may allow studies into the exact timing of signal termination, and determine whether the ligand remains bound to the receptor during the internalisation process. The pathway which a receptor takes upon internalization has been probed for the AT 1 angiotensin receptor with a fluorescent derivative of the endogenous agonist AngII using confocal microscopy. Using this fluorescent agonist they showed that the receptor localised with Rab5-positive early endosomes upon endocytosis and then with Rab11-positive recycling endosomes and Rab7-positive degradation lysosomes after long term agonist stimulation. In addition, it was demonstrated that inhibition of PI3 kinase prevented efficient recycling of the receptor to the cell surface (Hunyady et al., 2002) . Localisation of a fluorescent ligand with endosomal markers has also been observed for the vasopressin V2 receptor (Chen et al., 2011) Within this special themed issue, we have shown that a newly developed fluorescent agonist for adenosine receptors, containing a peptidic linker, can induce internalisation of the adenosine-A 3 receptor and co-localise with receptor/ arrestin3 complexes that have been trapped by biomolecular fluorescence complementation (Stoddart et al., 2015) . These examples demonstrate that it is possible to use fluorescent ligands to track the receptor/agonist complexes through multiple steps in the internalisation process.
Ligand-receptor binding kinetics
An often overlooked characteristic of a GPCR ligand is its binding kinetic parameters and it is becoming increasingly clear that the residence time of a ligand on a receptor may influence its effectiveness as a drug in the clinic (Vauquelin and Charlton, 2010) . Binding kinetics at a GPCR can be examined through radioligand binding experiments or using biophysical techniques such as surface plasmon resonance. Fluorescent ligands provide an alternative to allow the study of kinetics in living cells, as demonstrated for the adenosine-A 1 and -A 3 receptors (May et al., 2011; May et al., 2010) and the histamine-H 1 receptor (Schiele et al., 2014) . May et al. (2011) demonstrated that a fluorescent agonist for the adenosine receptors, ABA-X-BY630, could be used in conjunction with confocal microscopy and a high flow rate perfusion system to accurately measure the kinetics of agonist binding in single living cells. They further went on to show that allosteric modulators could influence the dissociation rate of ABA-X-BY630 . They also demonstrated the power of this technique to detect functional effects of receptor oligomerisation by examining the effect of orthosteric antagonists or agonists on the dissociation kinetics of the orthosteric fluorescent ligand. Unexpectedly, the presence of unlabelled orthosteric ligands increased the dissociation rate of ABA-X-BY630 from the adenosine-A 3 receptor. This was shown to be through the binding of low concentrations of the fluorescent ligand to one protomer of a receptor homodimer with a second unlabelled ligand enhancing the dissociation rate of the fluorescent ligand acting with a high degree of negative cooperativity across the dimer interface following binding to the second protomer (May et al., 2011) . This further demonstrates that fluorescent ligands can be used to study novel aspects of GPCR pharmacology.
Fluorescent ligands to probe receptor organisation in the membrane
In addition to the well characterised use of fluorescent ligands to identify the expression and localisation of receptors, they can be used in single molecule microscopy experiments (e.g., total internal reflection microscopy, TIRF-M; fluorescence correlation spectroscopy, FCS) to quantify the real time mobility of receptoreligand complexes in living cells, as a way of probing how the receptor is organised at the molecular level within the membrane.
FCS measures the diffusion of fluorescently labelled molecules through a small defined confocal volume, typically of~0.25 fL (0.2 Â 1 mm) (Ries and Schwille, 2012) . As fluorescent particles pass through this volume, they produce time-dependent fluctuations in intensity, whose frequency can be analysed using autocorrelation analysis to provide information about their mobility and concentration (Briddon and Hill, 2007) . The detection volume used in FCS encompasses a cellular region containing only~0.2 mm 2 of plasma membrane and typically contains 1e100 fluorescent particles. GPCRs have been shown to be spatially organised at the plasma membrane into discrete microdomains, through interactions with the cytoskeleton or the lipid environment (Cordeaux et al., 2008; Insel et al., 2005; Padgett et al., 2010) which may organise intracellular signalling components in close proximity (Corriden et al., 2014) and place barriers on the extent of lateral diffusion possible (Daumas et al., 2003; Suzuki et al., 2005) . It is therefore likely that the membrane region contained within the confocal volume is heterogeneous in respect to receptor expression, adding complexity to the identification of specific receptor complexes (He and Marguet, 2011) . However the use of fluorescent ligands with FCS can elucidate the molecular composition of signalling complexes due to the marked difference in molecular weight, and therefore diffusion characteristics, of free and receptor bound ligand, which can be deconvolved by autocorrelation analysis (Briddon and Hill, 2007) . Since the amplitude of the autocorrelation curve is inversely proportional to the concentration of fluorescent particles present within the confocal volume, this means that FCS is best suited to low concentrations of fluorescent ligand or receptor, and is therefore sensitive enough to be used where receptor expression is low (such as in native tissues) (Briddon and Hill, 2007; Diekmann and Hoischen, 2014) .
Fluorescent ligands have been shown to freely diffuse in three dimensions with a typical dwell time in the FCS detection volume of between 50 and 100 ms (Briddon and Hill, 2007) . However, interaction of fluorescent ligands with membrane bound receptors results in a marked slowing of their diffusion, since the receptor has a much larger molecular weight and is confined within a cell membrane. As autocorrelation functions of fluorescent species are additive, when the measurement volume contains both free and bound ligand, the autocorrelation curves produced consist of multiple components with differing dwell times (and hence diffusion coefficients). The fast moving component, termed t D1 , is representative of free fluorescent ligand, whereas one or more slower moving components represent ligand-receptor complexes (termed t D2 and/or t D3 respectively). To date, FCS in combination with fluorescent ligands has been used to characterise the histamine-H 1 receptor (Rose et al., 2012) , b 2 -adrenoceptor (Hegener et al., 2004; Prenner et al., 2007) , galanin receptor (Pramanik et al., 2001) , somatostatin receptor (Grant et al., 2004) and the adenosine-A 1 Middleton et al., 2007) and -A 3 (Cordeaux et al., 2008; Corriden et al., 2014) receptors. In all of these studies ligand-receptor complexes were shown to exist in two distinct diffusing components at the plasma membrane (designated t D2 and t D3 ), suggesting at least two states or populations of receptors exist. Dwell times for these components typically ranged from 1 to 20 ms for t D2 and 10 to 700 ms for t D3 (see Table 1 ). Interestingly, the proportion of t D2 or t D3 represented in the total fraction significantly differs between receptor types (Table 1) . Furthermore, the t D3 components detected have been proposed to represent different conformations of the ligand-receptor complex depending on the nature of the fluorescent ligand (agonist or antagonist) used (Briddon and Hill, 2007; Corriden et al., 2014) . For example, labelling with either fluorescent agonist (ABEA-X-BY630; Cordeaux et al., 2008) or antagonist (CA200645; Corriden et al., 2014) has been shown to differentially identify the high affinity active (R*) and inactive (R) forms of the adenosine-A 3 receptor which can be tracked by the characteristics of the t D3 component.
The low concentration of fluorescent ligands used in FCS would promote selective labelling of these different high affinity conformations. Additionally, the faster diffusing t D2 component in these experiments has been postulated to represent a receptor state where the fluorescent ligand has dissociated during the time taken for the complex to transit through the confocal volume (Corriden et al., 2014) . It is also worth considering, however, that both t D2 and t D3 may not represent distinct receptor states, but are rather a composite of diffusion coefficients consisting of multiple ligandreceptor complexes (Briddon and Hill, 2007) which may reflect the range of ligand specific conformational states proposed for GPCRs (Seifert, 2013) .
Additionally, many of the diffusion rates observed for t D3 derived from autocorrelation analysis are too slow to represent single receptor species implying the formation of macromolecular complexes indicative of receptor oligomerisation or clustering of signalling complexes (Corriden et al., 2014; Rose et al., 2012) . Additional indirect evidence for oligomerisation has also been observed, with evidence for negative cooperativity across a dimer interface observed from FCS washout experiments performed on adenosine-A 3 receptors labelled with the antagonist CA200645 and unlabelled competing agonist XAC (Corriden et al., 2014) . However relating changes in diffusion coefficients derived from autocorrelation analysis to changes in molecular mass, can often be problematic due to the cube root relationship that exists between the two factors (Briddon and Hill, 2007) . For example whilst the formation of a GPCR dimer from a monomer is a 2-fold change in mass, this only equates to a 1.25-fold change in diffusion coefficient. The use of photon counting histogram (PCH) analysis may go some way to addressing this, as a doubling in mass (i.e. monomer to dimer) theoretically results in a doubling in molecular brightness, which is detectable (Herrick-Davis et al., 2013; Muller et al., 2000) . PCH analysis has been used for GPCRs tagged with full length fluorescent proteins (Herrick-Davis et al., 2013; Kilpatrick et al., 2012) but as yet not been used with fluorescent ligands. FCS and other fluctuation based techniques in conjunction with fluorescent ligands can therefore be used to characterise populations of receptors within membrane microdomains, and FCS has provided important information on GPCR mobility, activation and oligomeric states.
Fluorescent ligands to study receptor dimerization
One way in which the organisation of receptors in the membrane and receptor dimerization has been probed using fluorescent ligands is TIRF-M. TIRF-M is a wide-field imaging technique that can excite fluorescent molecules within a thin section of a sample. This technique relies upon an evanescent wave being produced when light is totally internally reflected at the boundary of two media with different refractive indices (such as the glass/water interface occurring at a coverslip). As the distance from this interface increases, the intensity of this wave decays exponentially, meaning that the region of the sample excited is limited to a few hundred nanometres resulting in an improved signal to noise ratio (Fish, 2009 ). This sensitivity and restricted illumination depth makes TIRF-M ideal for single molecule imaging and particularly for tracking of individual receptors and receptor complexes over a timescale of seconds to provide information on their mobility and clustering (Hern et al., 2010) . TIRF in conjunction with fluorescent ligands has been used to investigate the dynamics of GPCR oligomerisation in living cells. One advantage of this is that the resolution of TIRF is sufficiently great enough to identify individual fluorescent ligand-receptor complexes, assuming a ligand is binding in a 1:1 stoichiometry. The labelled high affinity muscarinic-M 1 acetylcholine receptor antagonist, Cy3B-telenzepine, has been used in TIRF studies to track and quantify the random walk lateral diffusion of muscarinic-M 1 receptors in the plasma membrane of CHO cells and illustrated that the receptors can exist as monomers and transient dimers (Hern et al., 2010) . Interestingly dimers were found to only make up approximately 30% of the total receptor population. Dual colour labelling of receptors with both red (Cy3B) and green (Alexa488) telenzepine ligand in a 1:1 ratio revealed the kinetics of M 1 receptor dimer association and dissociation to be a dynamic process with a dimer half-life of 0.5 s. Similar results have also been observed for N-formyl peptide receptors identified using an agonist peptide conjugated to Alexa594, whereby at physiological receptor expression levels, rapid association of monomers into dimers (occurring every 150 ms) and dissociation of dimers (every 91 ms) was observed with the equilibria of these processes fully characterised for the first time (Kasai et al., 2011) . GPCR complexes with different organisational and dynamic properties have also been identified using SNAP-tag approaches (Calebiro et al., 2013) . Interestingly there are suggestions that the predominant receptor form may also be influenced by receptor expression levels with dimers the prevalent form at high receptor expression (although the dimer lifetime is unaffected), most likely due to greater receptor proximity increasing the likelihood of associations (Kasai and Kusumi, 2014) . TIRF in combination with fluorescent ligands can therefore be used to identify and track the mobility of receptor complexes in living cells at a single molecule resolution. It has given valuable information on the extent of dimer formation and the dynamic nature of this process in biologically relevant timescales.
Many of the above techniques used to investigate GPCR dimerization rely on the direct monitoring of the fluorescent ligands. An additional advantage of fluorescent ligands is their ability to be used in energy transfer techniques such as time resolved fluorescence resonance energy transfer (TR-FRET) which has been used in both heterologous and endogenous expressing systems to study receptor dimers. In TR-FRET, the donor fluorophore is based on a lanthanide label (such as europium or terbium), which has a much longer fluorescence lifetime (50e100 ms), a pronounced Stokes shift between excitation and emission maxima and multiple emission peaks, allowing it to be used with a variety of acceptor fluorophores (Albizu et al., 2010; Cottet et al., 2012) . This results in a time delay between the excitation and emission signal allowing separation from the much shorter-lived (1e10 ns) background fluorescence from the sample (Pramanik et al., 2001) and direct excitation of the acceptor, resulting in increased signal to noise ratios . TR-FRET can be used to investigate interactions of ligands binding to their cognate receptor such as for the growth hormone secretagogue type 1A receptor in HEK293T cells (Leyris et al., 2011) , dopamine-D 1 -D 5 receptor subtypes (Hounsou et al., 2014) and vasopressin V2 receptor (Loison et al., 2012) . Typically the lanthanide derivative is attached via a SNAP tag to the receptor where it acts as a donor for a fluorescently labelled ligand. TR-FRET observations between labelled ligands and vasopressin, oxytocin and dopamine-D 2 receptors have also provided evidence of negative cooperativity across receptor dimer interfaces, which are comparable to that seen for oxytocin receptors in native tissue (see below). Other receptorereceptor interactions have also been investigated using TR-FRET. Maurel et al. (2008) have used the SNAP substrate to link europium and d2 (an HTRF-specific fluorophore developed by Cisbio) fluorophores to the respective N termini of a range of Class A and C GPCRs in order to probe dimerisation (Maurel et al., 2008) . Interestingly this study implied that GABA B receptors form 'dimers of dimers' (see also Calebiro et al., 2013) and that the proportion of Class A GPCRs dimers formed may differ with expression level again reiterating that this is likely to be a dynamic process. A similar method using lanthanidelabelled SNAP and Halo tags has facilitated the investigation of the formation and pharmacological consequences of dopamine-D 1 and -D 3 receptor homo and heterodimerisation (Hounsou et al., 2014) .
Importantly, TR-FRET has been performed between differentially labelled fluorescent ligands in native tissue samples. For instance, europium (donor) and Alexa647 (acceptor)-labelled ligands were used to identify oxytocin receptor oligomers in membrane samples taken from lactating rat mammary gland tissue (Albizu et al., 2010) . Strong TR-FRET signals were observed with the simultaneous addition of labelled selective antagonists, implying close proximity of the two fluorophores and indirectly the formation of oxytocin dimers. Positive cooperativity was also observed indicating simultaneous occupancy by labelled antagonists for both ligand binding sites of the dimer. Conversely weak TR-FRET signals and efficacies were observed with deferentially labelled agonists, ). -High sensitivity, therefore can be used when receptor expression is low (such as often observed in native tissues). -Small assays volumes and ligand concentrations are used. This is particularly advantageous where ligands are expensive. -Multiple diffusion components can be isolated within one autocorrelation trace, providing quantitative information on different fluorescent complexes.
-FCS is only able to detect mobile fluorescent species. -Relatively low throughput, therefore is time consuming in respect to data acquisition and analysis. -Autocorrelation analysis assumes that the plasma membrane is in 2 dimensions, when some small regions have a 3 dimensional architecture (such as clathrin coated pits). -Due to the nature of autocorrelation function, it is difficult to derive changes in mass from this analysis alone. However combined use of PCH analysis allows this limitation to be addressed. Total internal reflection fluorescence microscopy (TIRF-M) -Capable of single molecule sensitivity; Good signal:noise ratio which decreases out of focus and background fluorescence resulting in increased z resolution. -Illumination is restricted to cellular regions at the interface region minimising phototoxic damage and photobleaching. This also allows for longer observation times. -A large range of fluorophores can be used. -Can be readily combined with other microscopy techniques -Imaging is limited to cellular regions close to the coverslip (due to the depth of penetration into the sample of the evanescent wave). -Requires objectives with high numerical aperture (>1.4NA) to produce the reflective angles required for generating evanescent waves. -Relatively low throughput.
Time resolved fluorescence resonance energy transfer (TR-FRET)
-Can study cellular interactions in living cells in real time.
-The longer fluorescence lifetime of lanthanides versus fluorophores used in standard FRET increases sensitivity and allows signals to be read after any interfering background fluorescence has decayed. Additionally lanthanide lifetimes are not dependent on local fluorophore intensity/concentrations, making TR-FRET particularly suitable for use in living specimens. -Time resolution allows the distances between the separation of donor and acceptor fluorophores to be quantified with greater accuracy when compared to FRET.
-Distance and orientation constraints exist for maximum efficiency of energy transfer between fluorophores (typically 10 nm). -To facilitate energy transfer, overlapping donor emission and acceptor absorption spectra are required. This can increase the risk of bleed through fluorescence. -A donor of sufficiently high quantum yield is required in order to minimise the influence of quenching. -Fluorescence lifetimes can be affected by local environmental conditions such as pH which can be difficult to control during the assay.
implying negative cooperativity across the dimer interface and single protomer ligand binding site occupancy. The changes in binding stoichiometry implied for agonist and antagonist fluorescent ligands were used as evidence against TR-FRET being caused by random 'bystander' interactions. TR-FRET is therefore not only able to investigate ligand binding and the formation of GPCR dimers in heterologous cell lines, but has great enough sensitivity to be used in native tissues. Additionally the nature of the pharmacophore used can probe the influence of cooperativity across the dimer interface in more physiologically relevant conditions.
Future directions and conclusions
The study of GPCRs using fluorescent ligands has advanced significantly in the last ten years not just in the range of techniques used but also in the rational design of fluorescent ligands and the mechanistic insights they have uncovered. Each of the techniques available to use in conjunction with fluorescent ligand have advantages but also limitations and these are summarized in Table 2 . The wealth of structural information derived from crystal structures of a wide range of GPCRs and improved in silico modelling (Kooistra et al., 2014) will hopefully allow a greater understanding of how a fluorescent ligand interacts with a receptor and what role the linker and fluorophore plays in this interaction. This should also lead to improved design of fluorescent ligands with specific properties and allow the selection of good ligandefluorophore pairs to be determined prior to extensive and expensive chemical synthesis. Structural knowledge will also help in the development of fluorescent ligands for specific imaging techniques. For example, fluorescent ligands have the potential to be useful in super-resolution microscopy but they require specific photophysical properties that are not common to all fluorophores. Super-resolution microscopy will also help with understanding the spatial expression of GPCRs and functional regulation in more detail that can be determined with current confocal microscopy (Jonas et al., 2014) . In conclusion, fluorescent ligands have been used to study a wide range of aspects of GPCR pharmacology and with the growth in this field they will continue to be a valuable asset in drug discovery and academic GPCR research.
